These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 29336432)
1. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Lewis JD; Scott FI; Brensinger CM; Roy JA; Osterman MT; Mamtani R; Bewtra M; Chen L; Yun H; Xie F; Curtis JR Am J Gastroenterol; 2018 Mar; 113(3):405-417. PubMed ID: 29336432 [TBL] [Abstract][Full Text] [Related]
2. Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease. Cohen-Mekelburg S; Wallace BI; Van T; Wiitala WL; Govani SM; Burns J; Lipson R; Yun H; Hou J; Lewis JD; Dominitz JA; Waljee AK JAMA Netw Open; 2021 Mar; 4(3):e210313. PubMed ID: 33646314 [TBL] [Abstract][Full Text] [Related]
3. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis. Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957 [TBL] [Abstract][Full Text] [Related]
4. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599 [TBL] [Abstract][Full Text] [Related]
5. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort. Jeuring SFG; Biemans VBC; van den Heuvel TRA; Zeegers MP; Hameeteman WH; Romberg-Camps MJL; Oostenbrug LE; Masclee AAM; Jonkers DMAE; Pierik MJ Am J Gastroenterol; 2018 Mar; 113(3):384-395. PubMed ID: 29317770 [TBL] [Abstract][Full Text] [Related]
6. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281 [TBL] [Abstract][Full Text] [Related]
7. Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. Scott FI; Johnson FR; Bewtra M; Brensinger CM; Roy JA; Reed SD; Osterman MT; Mamtani R; Chen L; Yun H; Xie F; Curtis JR; Lewis JD Inflamm Bowel Dis; 2019 Apr; 25(5):925-936. PubMed ID: 30535149 [TBL] [Abstract][Full Text] [Related]
8. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418 [TBL] [Abstract][Full Text] [Related]
9. Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014. Ludvigsson JF; Mahl M; Sachs MC; Björk J; Michaelsson K; Ekbom A; Askling J; Backman AS; Olén O Am J Gastroenterol; 2019 Feb; 114(2):291-304. PubMed ID: 30730858 [TBL] [Abstract][Full Text] [Related]
10. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607 [TBL] [Abstract][Full Text] [Related]
11. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308 [TBL] [Abstract][Full Text] [Related]
12. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study. Thomsen SB; Ungaro RC; Allin KH; Elmahdi R; Poulsen G; Andersson M; Colombel JF; Jess T Aliment Pharmacol Ther; 2022 May; 55(9):1128-1138. PubMed ID: 35080036 [TBL] [Abstract][Full Text] [Related]
13. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study. Seo J; Kim S; Hong SW; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Kim YJ; Ye BD Aliment Pharmacol Ther; 2024 Aug; 60(3):389-400. PubMed ID: 38866064 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases. Bank S; Andersen PS; Burisch J; Pedersen N; Roug S; Galsgaard J; Turino SY; Brodersen JB; Rashid S; Avlund S; Olesen TB; Green A; Hoffmann HJ; Thomsen MK; Thomsen VØ; Nexø BA; Vogel U; Andersen V Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748864 [TBL] [Abstract][Full Text] [Related]
15. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446 [TBL] [Abstract][Full Text] [Related]
16. Impact of antitumour necrosis factor therapy on surgery in inflammatory bowel disease: a population-based study. Hawthorne AB; Arms-Williams B; Cannings-John R; Pollok RCG; Berry A; Harborne P; Trivedi A BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38777566 [TBL] [Abstract][Full Text] [Related]
17. Trends and Outcomes of Hip Fracture Hospitalization Among Medicare Beneficiaries with Inflammatory Bowel Disease, 2000-2017. Xu F; Wheaton AG; Barbour KE; Liu Y; Greenlund KJ Dig Dis Sci; 2021 Jun; 66(6):1818-1828. PubMed ID: 32700169 [TBL] [Abstract][Full Text] [Related]
18. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804 [TBL] [Abstract][Full Text] [Related]
19. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Card T; West J; Hubbard R; Logan RF Gut; 2004 Feb; 53(2):251-5. PubMed ID: 14724159 [TBL] [Abstract][Full Text] [Related]